問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

National Taiwan University Hospital Hsin-Chu Branch

Division of General Internal Medicine

更新時間:2023-09-19

謝松洲HSIEH, SONG-CHOU
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

篩選

List

93Cases

2023-09-01 - 2028-02-29

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

2016-04-01 - 2020-11-30

Phase III

Completed
A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis
  • Condition/Disease

    Moderately to Severely Active Rheumatoid Arthritis

  • Test Drug

    ABT-494

Participate Sites
4Sites

Terminated3Sites

2021-10-01 - 2023-08-04

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2014-02-14 - 2015-12-31

Others

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2024-07-01 - 2027-01-31

Phase II

Active
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome
  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    injection

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2022-10-31 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-09-16 - 2031-12-31

Phase II

Active
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis)
  • Condition/Disease

    Radiographic Axial Spondyloarthritis

  • Test Drug

    皮下注射劑

Participate Sites
7Sites

Recruiting7Sites

2018-08-01 - 2025-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2024-07-17 - 2027-07-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites